Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Arrowhead Promotes David Lewis to Chief Scientific Officer: Steven Kanner Joins the Company as Vice President of Biology

Abstract:
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced the promotion of David Lewis, Ph.D., to Chief Scientific Officer. In this position, Dr. Lewis will have overall scientific leadership responsibilities for RNA delivery, discovery, and pre-clinical development of new drug candidates.

Arrowhead Promotes David Lewis to Chief Scientific Officer: Steven Kanner Joins the Company as Vice President of Biology

Pasadena, CA | Posted on September 20th, 2013

Dr. Lewis is a leading expert in nucleic acid delivery and RNAi therapeutics with over ten years of experience in the field. He is a co-inventor of the Dynamic Polyconjugate® (DPC) technology for targeted delivery of siRNA and led the discovery and pre-clinical development program for ARC-520, Arrowhead's clinical candidate against chronic hepatitis B virus infection.

"Dave has served as the site head of the R&D facility in Madison for the last 3 years and has done a superb job of leading ARC-520 into clinical development and, in the process, expanding the site's development capabilities rapidly", said Bruce D. Given, MD, COO and Head of R&D for Arrowhead. "This recognition of his performance is richly deserved."

Arrowhead is also pleased to announce that Steven Kanner, Ph.D., has joined the company as Vice President of Biology to assume Dr. Lewis' prior responsibilities in this role. Dr. Kanner was previously Vice President, Discovery Biology at Astex Pharmaceuticals and held leadership and research roles at Agensys, Astellas, and Bristol-Myers Squibb. He received his B.A. degree in Genetics from the University of California-Berkeley, and his Ph.D. degree in Immunology and Microbiology from the University of Miami School of Medicine.

About ARC-520

Approximately 350 million people worldwide are chronically infected with the hepatitis B virus. Chronic HBV infection can lead to cirrhosis of the liver and is responsible for 80% of primary liver cancers globally. Arrowhead's RNAi-based candidate ARC-520 is designed to treat chronic HBV infection by reducing the expression and release of new viral particles and key viral proteins. The goal is to achieve a functional cure, which is an immune clearant state characterized by hepatitis B s-antigen negative serum with or without sero-conversion. The siRNAs in ARC-520 intervene at the point of DNA transcription, upstream of where nucleotide and nucleoside analogues act. In transient and transgenic mouse models of HBV infection, a single co-injection of Arrowhead's DPC delivery vehicle with cholesterol-conjugated siRNA targeting HBV sequences resulted in multi-log knockdown of HBV RNA, proteins and viral DNA with long duration of effect. In a chimpanzee chronically infected with HBV and high viremia and antigenemia, ARC-520 induced rapid reductions of 90-95% in HBV DNA, e-antigen, and s-antigen. Arrowhead is conducting a phase 1 single ascending dose study in normal volunteers, which the company expects to follow with a phase 2a study in chronic HBV patients.

####

About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silence disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead's pipeline includes clinical programs in chronic hepatitis B virus and obesity and partner-based programs in oncology.

For more information please visit www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to

NASDAQ Notice

As an inducement to his entering into employment with the Company on September 16, 2013, Dr. Kanner was awarded an "inducement" option under Rule 5635(c)(4) of the NASDAQ Marketplace Rules. The option entitles Dr. Kanner to purchase, outside of the Company's stockholder approved equity incentive plans, an aggregate of up to 50,000 shares of the Company's common stock at an exercise price per share of $4.65, the last reported closing price of the Company's common stock on the date of grant. The option vests and becomes exercisable over a period of four years from the date of grant.

For more information, please click here

Contacts:
Arrowhead Research
Vince Anzalone, CFA
626-304-3400

The Trout Group, LLC
Lauren Glaser
646-378-2972

Copyright © Arrowhead Research Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

University of Tehran Researchers Invent Non-Enzyme Sensor to Detect Blood Sugar April 23rd, 2014

Gold nanoparticles help target, quantify breast cancer gene segments in a living cell April 23rd, 2014

Study finds long-term survival of human neural stem cells transplanted into primate brain April 23rd, 2014

High-Performance, Low-Cost Ultracapacitors Built with Graphene and Carbon Nanotubes: Future devices based on technology could bridge gap between batteries and conventional capacitors in portable electronics and hybrid electric vehicles April 23rd, 2014

Nanomedicine

University of Tehran Researchers Invent Non-Enzyme Sensor to Detect Blood Sugar April 23rd, 2014

Gold nanoparticles help target, quantify breast cancer gene segments in a living cell April 23rd, 2014

QuantuMDx announce prototype handheld lab for 15 minute malaria diagnosis and drug resistance testing April 23rd, 2014

Study finds long-term survival of human neural stem cells transplanted into primate brain April 23rd, 2014

Announcements

Characterizing inkjet inks: Malvern Instruments presents new rheological research April 23rd, 2014

NanoSafe, Inc. announces the addition of the Labconco Protector® Glove Box to its NanoSafe Tested™ registry April 23rd, 2014

Study finds long-term survival of human neural stem cells transplanted into primate brain April 23rd, 2014

High-Performance, Low-Cost Ultracapacitors Built with Graphene and Carbon Nanotubes: Future devices based on technology could bridge gap between batteries and conventional capacitors in portable electronics and hybrid electric vehicles April 23rd, 2014

Appointments/Promotions/New hires/Resignations/Deaths

Nanobiotix Appoints Thierry Otin as Head of Manufacturing and Supply April 15th, 2014

Industry Veteran Fergus Clarke Joins Picodeon as CEO: Appointment comes as Picodeon prepares for growth April 8th, 2014

Peter B. Littlewood appointed Director of Argonne National Laboratory March 26th, 2014

Global 450 consortium announces new general manager of internal operations: TSMC’s Cheng-Chung Chien Receives Unanimous Support, Brings History of Innovation and Efficiency to Global Consortium of Companies Driving Industry Transition to 450mm Wafer Technology March 26th, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE